These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 36776024)

  • 1. Design, synthesis, docking, and anticancer evaluations of new thiazolo[3,2-
    El-Zoghbi MS; El-Sebaey SA; Al-Ghulikah HA; Sobh EA
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2175209. PubMed ID: 36776024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New pyranopyrazole based derivatives: Design, synthesis, and biological evaluation as potential topoisomerase II inhibitors, apoptotic inducers, and antiproliferative agents.
    Sobh EA; Kassab AE; El-Khouly EA; S A Hassan M
    Bioorg Chem; 2024 Mar; 144():107158. PubMed ID: 38301427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel topoisomerase II/EGFR dual inhibitors: design, synthesis and docking studies of naphtho[2',3':4,5]thiazolo[3,2-
    Mourad MAE; Abo Elmaaty A; Zaki I; Mourad AAE; Hofni A; Khodir AE; Aboubakr EM; Elkamhawy A; Roh EJ; Al-Karmalawy AA
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2205043. PubMed ID: 37165800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
    El-Adl K; El-Helby AA; Sakr H; Elwan A
    Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers.
    Abbass EM; Khalil AK; Mohamed MM; Eissa IH; El-Naggar AM
    Bioorg Chem; 2020 Nov; 104():104255. PubMed ID: 32927130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacophore-based, rationale design, and efficient synthesis of novel tetrahydrobenzo[b]thiophene candidates as potential dual Topo I/II inhibitors and DNA intercalators.
    Nofal HR; Al-Karmalawy AA; Elmaaty AA; Ismail MF; Ali AK; Abbass EM
    Arch Pharm (Weinheim); 2024 Sep; 357(9):e2400217. PubMed ID: 38864845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors.
    Eissa IH; Metwaly AM; Belal A; Mehany ABM; Ayyad RR; El-Adl K; Mahdy HA; Taghour MS; El-Gamal KMA; El-Sawah ME; Elmetwally SA; Elhendawy MA; Radwan MM; ElSohly MA
    Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900123. PubMed ID: 31463953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New fused pyrimidine derivatives with anticancer activity: Synthesis, topoisomerase II inhibition, apoptotic inducing activity and molecular modeling study.
    Nemr MTM; AboulMagd AM
    Bioorg Chem; 2020 Oct; 103():104134. PubMed ID: 32750610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
    Kassab AE; Gedawy EM
    Eur J Med Chem; 2018 Apr; 150():403-418. PubMed ID: 29547830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel triazolophthalazine derivatives as DNA intercalators and topoisomerase II inhibitors.
    Sakr H; Ayyad RR; El-Helby AA; Khalifa MM; Mahdy HA
    Arch Pharm (Weinheim); 2021 Jun; 354(6):e2000456. PubMed ID: 33554352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, molecular modeling and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as inhibitors of topoisomerase II.
    El-Metwally SA; Khalil AK; El-Sayed WM
    Bioorg Chem; 2020 Jan; 94():103492. PubMed ID: 31864673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-target rational design and synthesis of novel diphenyl-tethered pyrazolopyrimidines targeting EGFR and topoisomerase II with potential DNA intercalation and apoptosis induction.
    Gaber AA; Abo Elmaaty A; Sharaky M; Mosa AA; Yahya Abdullah Alzahrani A; Shaaban S; Eldehna WM; Al-Karmalawy AA
    Bioorg Chem; 2024 Apr; 145():107223. PubMed ID: 38387399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of novel rigid dibenzo[
    El-Behairy MF; Abd-Allah WH; Khalifa MM; Nafie MS; Saleh MA; Abdel-Maksoud MS; Al-Warhi T; Eldehna WM; Al-Karmalawy AA
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2157825. PubMed ID: 36629421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and antiproliferative evaluation of new tricyclic fused thiazolopyrimidines targeting topoisomerase II: Molecular docking and apoptosis inducing activity.
    Nemr MTM; Sonousi A; Marzouk AA
    Bioorg Chem; 2020 Dec; 105():104446. PubMed ID: 33171405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel 6,7,8-trihydrobenzo[6',7']cyclohepta[2',1'-e]pyrazolo[2,3-a]pyrimidine derivatives as Topo IIα inhibitors with potential cytotoxic activity.
    Farghaly TA; Gaber Abdulwahab H; Medrasi HY; Al-Sheikh MA; Katowah DF; Alsaedi AMR
    Bioorg Chem; 2022 Nov; 128():106043. PubMed ID: 36058118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and biological evaluation of novel ciprofloxacin derivatives as potential anticancer agents targeting topoisomerase II enzyme.
    Swedan HK; Kassab AE; Gedawy EM; Elmeligie SE
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):118-137. PubMed ID: 36305290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational Design, Synthesis, Molecular Docking, and Biological Evaluations of New Phenylpiperazine Derivatives of 1,2-Benzothiazine as Potential Anticancer Agents.
    Szczęśniak-Sięga BM; Zaręba N; Czyżnikowska Ż; Janek T; Kepinska M
    Molecules; 2024 Sep; 29(18):. PubMed ID: 39339277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and
    Khalifa MM; Al-Karmalawy AA; Elkaeed EB; Nafie MS; Tantawy MA; Eissa IH; Mahdy HA
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):299-314. PubMed ID: 34894955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triazoloquinoxalines-based DNA intercalators-Topo II inhibitors: design, synthesis, docking, ADMET and anti-proliferative evaluations.
    Elwan A; Sakr H; El-Helby AA; El-Morsy A; Abdelgawad MA; Ghoneim MM; El-Sherbiny M; El-Adl K
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1556-1567. PubMed ID: 35635148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors.
    Ibrahim MK; Taghour MS; Metwaly AM; Belal A; Mehany ABM; Elhendawy MA; Radwan MM; Yassin AM; El-Deeb NM; Hafez EE; ElSohly MA; Eissa IH
    Eur J Med Chem; 2018 Jul; 155():117-134. PubMed ID: 29885574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.